

October 4, 2021



# Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

HARRISON, N.Y., Oct. 4, 2021 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that it will present an oral presentation on its lead program, ST101, at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. The meeting is being held in a virtual format from October 7-10<sup>th</sup>, 2021.

Oral presentation details are as follows:

**Date/Time:** Saturday, October 9, 2021, 4:00 pm-5:40 pm ET

**Session:** Plenary Session 6, New Drugs on the Horizon II

**Abstract Number:** #4993

**Abstract/Presentation Title:** ST101, a peptide targeting oncogenic transcription factor C/EBP $\beta$ : Initial safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data from an ongoing phase 1 dose escalation study in patients with advanced metastatic solid tumors

## **About ST101**

ST101, a peptide antagonist of C/EBP $\beta$ , is currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors ([NCT04478279](#)). In the ongoing study, ST101 has demonstrated clinical proof-of-concept with a RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. Following conclusion of the final dose-escalation cohort, Sapience plans to initiate four Phase 2 expansion cohorts in refractory, locally advanced and metastatic cutaneous melanoma, hormone-receptor-positive breast cancer, castrate-resistant prostate cancer, and glioblastoma starting in the second half of 2021. ST101 has been granted orphan drug product designation from the U.S. Food and Drug Administration and orphan medicinal product designation for the treatment of glioma by the European Commission.

## **About Sapience Therapeutics**

Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide

therapeutics that disrupt protein-protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit [www.sapiencetherapeutics.com](http://www.sapiencetherapeutics.com) and engage with us on LinkedIn.

### ***Cautionary Note on Forward-Looking Statements***

This press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.

### **Contacts**

Sapience Therapeutics, Inc.:  
Barry Kappel, Ph.D., M.B.A.  
President and Chief Executive Officer  
[info@sapiencetherapeutics.com](mailto:info@sapiencetherapeutics.com)

### **Media and Investor Contact:**

Amy Conrad  
Juniper Point  
(858) 366-3243  
[amy@juniper-point.com](mailto:amy@juniper-point.com)

🔗 View original content:<https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-oral-presentation-on-st101-at-the-aacr-nci-eortc-virtual-international-conference-on-molecular-targets-and-cancer-therapeutics-2021-301391710.html>

SOURCE Sapience Therapeutics, Inc.